Cameron S. Thorpe

Cameron S. Thorpe

Auto-generated profile, based on publicly available information

Cameron S. Thorpe

Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Expert Review of Cardiovascular Therapy
Verified
Journal Article
Closed access
JNJoshua R. Niska
Joshua R. Niska
CTCameron S. Thorpe
Cameron S. Thorpe
SASorcha M. Allen
Sorcha M. Allen
TDThomas B. Daniels
Thomas B. Daniels
WRWilliam G. Rule
William G. Rule
FMFarouk Mookadam
Farouk Mookadam
Introduction: Recent trials in radiotherapy have associated heart dose and survival, inadequately explained by the existing literature for radiation-related late cardiac effects. Authors aimed to review the recent literature on cardiac dosimetry and survival/cardiac endpoints. Areas covered: A systematic review of the literature in the past 10 years (2008-2017) was performed to identify manuscripts reporting both cardiac dosimetry and survival/cardiac endpoints. Authors identified 64 manuscripts for inclusion, covering pediatrics, breast cancer, lung cancer, gastrointestinal diseases (primarily esophageal cancer), and adult lymphoma. Expert commentary: In the first years after radiotherapy, high doses (>40 Gy) to small volumes of the heart are associated with decreased survival from an unknown cause. In the long-term, mean heart dose is associated with a small increased absolute risk of cardiac death. For coronary disease, relative risk increases roughly 10% per Gy mean heart dose, augmented by age and cardiac risk factors. For valvular disease and heart failure, doses >15 Gy substantially increase risk, augmented by anthracyclines. Arrhythmias after radiotherapy are poorly described but may account for the association between upper heart dose and survival. Symptomatic pericardial effusion typically occurs with doses >40 Gy. Close follow-up and mitigation of cardiovascular risk factors is necessary after thoracic radiotherapy.

23 July 2019 in The Breast Journal
Verified
Journal Article
Closed access
PDF file
CTCameron S. Thorpe
Cameron S. Thorpe
JNJoshua R. Niska
Joshua R. Niska
MGMarlene E. Girardo
Marlene E. Girardo
HKHeidi E. Kosiorek
Heidi E. Kosiorek
LMLisa A. McGee
Lisa A. McGee
CVCarlos E Vargas
Carlos E Vargas

1 August 2016 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
JTJonathan David Tward
Jonathan David Tward
SJStephanie Jarosek
Stephanie Jarosek
HCHaitao Chu
Haitao Chu
CTCameron Thorpe
Cameron Thorpe
DSDennis C. Shrieve
Dennis C. Shrieve
SESean Elliott
Sean Elliott

1 November 2017 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
SFSamual R. Francis
Samual R. Francis
AOAndrew Orton
Andrew Orton
CTCameron Thorpe
Cameron Thorpe
GSGreg Stoddard
Greg Stoddard
SLShane Lloyd
Shane Lloyd
CAChristopher J. Anker
Christopher J. Anker

1 August 2018 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
MHMatthew M. Harkenrider
Matthew M. Harkenrider
BMBrendan Martin
Brendan Martin
KNKarina Nieto
Karina Nieto
CSChristina Small
Christina Small
IAIbrahim Aref
Ibrahim Aref
WSWilliam Small
William Small

1 December 2016 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
DBDustin Boothe
Dustin Boothe
AOAndrew Orton
Andrew Orton
CTCameron Thorpe
Cameron Thorpe
KKKristine Kokeny
Kristine Kokeny
YHYing J. Hitchcock
Ying J. Hitchcock